DGX

Quest Diagnostics
D

DGX

Arincen63/100B

Quest Diagnostics company profile

CEO
James E. Davis
Employees
57,000
Headquarters
500 Plaza Drive, Secaucus, NJ 07094, US
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO date
17 Dec 1996
Stock exchange
NYSE
ISIN
US74834L1008

Website:questdiagnostics.com

About the company

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Employees

Quest Diagnostics had about 57,000 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 1.8% more than a year before.

Employees Change on the year
Fiscal yearEmployeesChange on the yearRevenue per employeeNet income per employee
FY202557,000+1.79%193.60K USD17.40K USD
FY202456,000+40.00%176.29K USD15.55K USD
FY202340,0000.00%231.30K USD21.35K USD
FY202240,0000.00%247.08K USD23.65K USD
FY202140,0000.00%269.70K USD49.88K USD
FY202040,000-14.89%235.93K USD35.78K USD
FY201947,000+2.17%164.38K USD18.26K USD
FY201846,000+2.22%163.72K USD16.00K USD
FY201745,000+4.65%171.31K USD17.16K USD
FY201643,000-2.27%174.77K USD15.00K USD
FY201544,000-2.22%170.30K USD16.11K USD
FY201445,000+9.76%165.22K USD12.36K USD
FY201341,0000.00%174.29K USD20.71K USD
FY201241,000-2.38%180.06K USD13.55K USD
FY201142,0000.00%178.82K USD11.20K USD
FY201042,000-2.33%175.45K USD17.16K USD
FY200943,000+0.47%173.38K USD16.96K USD
FY200842,800-1.61%169.38K USD13.59K USD
FY200743,500+6.10%154.14K USD7.81K USD
FY200641,000-1.20%152.89K USD14.30K USD
FY200541,500+7.51%132.62K USD13.16K USD
FY200438,600+3.76%132.81K USD12.93K USD
FY200337,200+807.32%127.36K USD11.74K USD
FY20024,100+36.67%1.00M USD78.57K USD
FY20013,000-88.89%1.21M USD54.10K USD
FY200027,0000.00%126.71K USD3.78K USD
FY199927,000+80.00%81.67K USD-125.93 USD
FY199815,000-18.03%97.24K USD1.79K USD
FY199718,300+2.81%83.54K USD-1.22K USD
FY199617,800—90.80K USD-35.17K USD

Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.

Who owns Quest Diagnostics

Institutions such as funds, banks and insurers held 96.1% of Quest Diagnostics's shares on 30 June 2026, 1,128 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.

Institutions 96.1%Other shareholders 3.9%

Shares free to trade

Free float 109.49M shares ·99.2% Closely held 879.59K shares ·0.8%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Common questions about Quest Diagnostics

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.